
Applied Therapeutics Investor Relations Material
Latest events

Study Result
Applied Therapeutics

Q1 2025
13 May, 2025

Q4 2024
14 Apr, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Applied Therapeutics Inc
Access all reports
Applied Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing innovative drugs for conditions with significant unmet medical needs. The company focuses on novel drug candidates targeting validated molecular pathways in diseases such as Galactosemia, Diabetic Cardiomyopathy, Diabetic Peripheral Neuropathy, and other areas with high unmet medical needs. Among its pipeline, notable drug candidates include AT-001, an aldose reductase inhibitor for diabetic complications; AT-007 for rare diseases such as SORD Deficiency; and AT-003, designed for diabetic retinopathy. Additionally, Applied Therapeutics is exploring AT-104, a PI3K inhibitor for orphan hematological oncology, specifically T Cell Acute Lymphoblastic Leukaemia. Applied Therapeutics is headquartered in New York, NY, and its shares are listed on the NASDAQ.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
APLT
Country
🇺🇸 United States